Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Moodys
AstraZeneca
Johnson and Johnson
Colorcon

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR VICODIN HP

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Vicodin Hp

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00174538 Codeine in Sickle Cell Disease Completed PriCara, Unit of Ortho-McNeil, Inc. Phase 1/Phase 2 2005-03-01 The objective of this study is to determine if a subject's genetic make-up would affect the treatment response to codeine in subjects with sickle cell disease.
NCT00195728 Long Term Safety and Tolerability Study in Approximately 350 Subjects With Moderate to Severe Chronic, Non-malignant Pain Completed Abbott Phase 3 2005-06-01 The purpose of the study is to evaluate the safety of Vicodin CR (combination opioid and acetaminophen containing product) in patients with chronic pain due to osteoarthritis or low back pain.
NCT00298974 A Study of Pain Relief in Osteoarthritis Completed Abbott Phase 3 2006-02-01 The purpose of this study is to compare the safety and pain-relieving ability of Vicodin CR to placebo in subjects with osteoarthritis (OA) of the hip or knee.
NCT00304317 Celecoxib (Celebrex) in the Management of Acute Renal Colic Terminated Pfizer Phase 4 2006-03-01 The purpose of this trial is to quantify the amount Celebrex, a specific cyclooxygenase-2 (COX-2) inhibitor, when used for the management of acute renal colic for a ureteral stone will: - reduce pain medication usage - improve the percentage of spontaneous stone passage - decrease the time to spontaneous passage, and - shift the size distribution of stones passed towards larger sizes
NCT00304317 Celecoxib (Celebrex) in the Management of Acute Renal Colic Terminated University of Minnesota - Clinical and Translational Science Institute Phase 4 2006-03-01 The purpose of this trial is to quantify the amount Celebrex, a specific cyclooxygenase-2 (COX-2) inhibitor, when used for the management of acute renal colic for a ureteral stone will: - reduce pain medication usage - improve the percentage of spontaneous stone passage - decrease the time to spontaneous passage, and - shift the size distribution of stones passed towards larger sizes
NCT00312572 Safety and Efficacy of Dose Conversion From Vicodin® to Buprenorphine Transdermal System (Butrans™) in Subjects With OA Pain Completed Purdue Pharma LP Phase 3 2003-06-01 The objective of this study is to evaluate the safety and efficacy of dose conversion from hydrocodone/ acetaminophen (Vicodin®) to the buprenorphine transdermal system (Butrans™) in subjects with osteoarthritis pain of the hip or knee. The double-blind treatment intervention duration is 2 weeks during which time supplemental analgesic medication will be allowed.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Vicodin Hp

Condition Name

Condition Name for Vicodin Hp
Intervention Trials
Pain 9
Pain, Postoperative 3
Osteoarthritis 3
Chronic Low Back Pain 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Vicodin Hp
Intervention Trials
Pain, Postoperative 5
Osteoarthritis 4
Low Back Pain 3
Back Pain 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Vicodin Hp

Trials by Country

Trials by Country for Vicodin Hp
Location Trials
United States 163
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Vicodin Hp
Location Trials
Texas 10
Massachusetts 8
New York 7
Maryland 7
Florida 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Vicodin Hp

Clinical Trial Phase

Clinical Trial Phase for Vicodin Hp
Clinical Trial Phase Trials
Phase 4 12
Phase 3 8
Phase 2 6
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Vicodin Hp
Clinical Trial Phase Trials
Completed 21
Not yet recruiting 5
Recruiting 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Vicodin Hp

Sponsor Name

Sponsor Name for Vicodin Hp
Sponsor Trials
Abbott 8
AbbVie (prior sponsor, Abbott) 2
Maimonides Medical Center 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Vicodin Hp
Sponsor Trials
Other 24
Industry 17
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Johnson and Johnson
McKesson
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.